Page 40 - Read Online

Page 12 of 15 Benhammou et al. Hepatoma Res 2020;6:35 I http://dx.doi.org/10.20517/2394-5079.2020.16

20. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin 2017;67:7-30.
21. Welzel TM, Graubard BI, Quraishi S, Zeuzem S, Davila JA, et al. Population-attributable fractions of risk factors for hepatocellular
carcinoma in the United States. Am J Gastroenterol 2013;108:1314-21.
22. Kanwal F, Kramer JR, Mapakshi S, Natarajan Y, Chayanupatkul M, et al. Risk of hepatocellular cancer in patients with non-alcoholic
fatty liver disease. Gastroenterology 2018;155:1828-37.e2.
23. Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular
carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1.
24. Ioannou GN, Green P, Kerr KF, Berry K. Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related
cirrhosis for risk stratification. J Hepatol 2019;71:523-33.
25. Younossi Z, Stepanova M, Ong JP, Jacobson IM, Bugianesi E, et al. Nonalcoholic steatohepatitis is the fastest growing cause of
hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol 2019;17:748-55.e3.
26. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients
with hepatocellular carcinoma in the U.S. Hepatology 2014;59:2188-95.
27. Wong RJ, Aguilar M, Cheung R, Perumpail RB, Harrison SA, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver
disease among adults awaiting liver transplantation in the United States. Gastroenterology 2015;148:547-55.
28. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, et al. International trends in liver cancer incidence, overall and by histologic
subtype, 1978-2007. Int J Cancer 2016;139:1534-45.
29. Kawamura Y, Arase Y, Ikeda K, Seko Y, Imai N, et al. Large-scale long-term follow-up study of Japanese patients with non-alcoholic
Fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012;107:253-61.
30. Alexander M, Loomis AK, van der Lei J, Duarte-Salles T, Prieto-Alhambra D, et al. Risks and clinical predictors of cirrhosis and
hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts.
BMC Med 2019;17:95.
31. Haldar D, Kern B, Hodson J, Armstrong MJ, Adam R, et al. Outcomes of liver transplantation for non-alcoholic steatohepatitis: a
European Liver Transplant Registry study. J Hepatol 2019;71:313-22.
32. Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol 2017;67:862-73.
33. Wong MCS, Huang JLW, George J, Huang J, Leung C, et al. The changing epidemiology of liver diseases in the Asia-Pacific region. Nat
Rev Gastroenterol Hepatol 2019;16:57-73.
34. Cho EJ, Kwack MS, Jang ES, You SJ, Lee JH, et al. Relative etiological role of prior hepatitis B virus infection and nonalcoholic fatty
liver disease in the development of non-B non-C hepatocellular carcinoma in a hepatitis B-endemic area. Digestion 2011;84:17-22.
35. Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, et al. Risk for development of severe liver disease in lean patients with nonalcoholic
fatty liver disease: a long-term follow-up study. Hepatol Commun 2018;2:48-57.
36. Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, Horton JD, et al. Prevalence of hepatic steatosis in an urban population in the
United States: impact of ethnicity. Hepatology 2004;40:1387-95.
37. Caldwell SH, Harris DM, Patrie JT, Hespenheide EE. Is NASH underdiagnosed among African Americans? Am J Gastroenterol
2002;97:1496-500.
38. Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol
2004;99:292-8.
39. Schwimmer JB, Celedon MA, Lavine JE, Salem R, Campbell N, et al. Heritability of nonalcoholic fatty liver disease. Gastroenterology
2009;136:1585-92.
40. Loomba R, Schork N, Chen CH, Bettencourt R, Bhatt A, et al. Heritability of hepatic fibrosis and steatosis based on a prospective twin
study. Gastroenterology 2015;149:1784-93.
41. Romeo S, Kozlitina J, Xing C, Pertsemlidis A, Cox D, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty
liver disease. Nat Genet 2008;40:1461-5.
42. Dongiovanni P, Donati B, Fares R, Lombardi R, Mancina RM, et al. PNPLA3 I148M polymorphism and progressive liver disease. World
J Gastroenterol 2013;19:6969-78.
43. Smagris E, BasuRay S, Li J, Huang Y, Lai KM, et al. Pnpla3I148M knockin mice accumulate PNPLA3 on lipid droplets and develop
hepatic steatosis. Hepatology 2015;61:108-18.
44. Sookoian S, Pirola CJ. Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene
(PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883-94.
45. Liu YL, Patman GL, Leathart JB, Piguet AC, Burt AD, et al. Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased
risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. J Hepatol 2014;61:75-81.
46. Kozlitina J, Smagris E, Stender S, Nordestgaard BG, Zhou HH, et al. Exome-wide association study identifies a TM6SF2 variant that
confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2014;46:352-6.
47. Falleti E, Cussigh A, Cmet S, Fabris C, Toniutto P. PNPLA3 rs738409 and TM6SF2 rs58542926 variants increase the risk of
hepatocellular carcinoma in alcoholic cirrhosis. Dig Liver Dis 2016;48:69-75.
48. Mancina RM, Dongiovanni P, Petta S, Pingitore P, Meroni M, et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic
fatty liver disease in individuals of european descent. Gastroenterology 2016;150:1219-30.e6.
49. Luukkonen PK, Zhou Y, Hyötyläinen T, Leivonen M, Arola J, et al. The MBOAT7 variant rs641738 alters hepatic phosphatidylinositols
and increases severity of non-alcoholic fatty liver disease in humans. J Hepatol 2016;65:1263-5.
50. Donati B, Dongiovanni P, Romeo S, Meroni M, McCain M, et al. MBOAT7 rs641738 variant and hepatocellular carcinoma in non-